A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

NCT02173301 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: XP23829 400 mg QD
DRUG: XP 23829 800 mg QD
DRUG: XP23829 400 mg BID
DRUG: Placebo

Sponsor

Dr. Reddy's Laboratories Limited

Collaborators

[object Object]